Correction to: A Bowman–Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition (Cell Death Di scovery, (2016), 2, 1, (15067), 10.1038/cddiscovery.2015.67);A bowman–birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Mehdad, A ^a   Brumana, G ^a   Souza, A A ^a   Barbosa, J A R G ^a   Ventura, M M ^a   de Freitas, S M ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85009182975     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/s41420-024-02155-4     Document Type: Erratum

References (74)

1. Globocan. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012; 2012.
2. St Clair WH, Billings PC, Carew JA, Keller-McGandy C, Newberne P, Kennedy AR. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res 1990; 50: 580–586.
3. Billings PC, Newberne PM, Kennedy AR. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990; 11: 1083–1086.
4. Clemente A, Moreno FJ, Marin-Manzano Mdel C, Jimenez E, Domoney C. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Mol Nutr Food Res 2010; 54: 396–405.
5. Kennedy AR, Billings PC, Maki PA, Newberne P. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 1993; 19: 191–200.
6. Messadi DV, Billings P, Shklar G, Kennedy AR. Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst 1986; 76: 447–452.
7. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL Jr. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000; 9: 43–47.
8. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6: 4684–4691.
9. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M et al. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res 2013; 6: 410–418.
10. von Hofe E, Newberne PM, Kennedy AR. Inhibition of N-nitrosomethylbenzylamine-induced esophageal neoplasms by the Bowman-Birk protease inhibitor. Carcinogenesis 1991; 12: 2147–2150.
11. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276–1283.
12. Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K et al. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 2001; 48: 16–28.
13. Joanitti GA, Azevedo RB, Freitas SM. Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds. Cancer Lett 2010; 293: 73–81.
14. Chen YW, Huang SC, Lin-Shiau SY, Lin JK. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005; 26: 1296–1306.
15. Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR. Characterization of bortezomib-adapted I-45 mesothelioma cells. Mol Cancer 2010; 9: 110.
16. Sadoul R, Fernandez PA, Quiquerez AL, Martinou I, Maki M, Schroter M et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J 1996; 15: 3845–3852.
17. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855–860.
18. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893–12896.
19. Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001; 10: 1049–1059.
20. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004; 279: 11680–11685.
21. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14: 628–634.
22. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349–360.
23. Maharjan S, Oku M, Tsuda M, Hoseki J, Sakai Y. Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep 2014; 4: 5896.
24. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006; 57: 545–553.
25. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000; 5: 415–418.
26. Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl) 1996; 74: 297–312.
27. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062–1075.
28. Fan XM, Wong BC, Wang WP, Zhou XM, Cho CH, Yuen ST et al. Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 2001; 93: 481–488.
29. Xiang T, Du L, Pham P, Zhu B, Jiang S. Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. Cancer Lett 2015; 364: 79–88.
30. Oliveira CS, Pereira H, Alves S, Castro L, Baltazar F, Chaves SR et al. Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria. Cell Death Dis 2015; 6: e1788.
31. Papa L, Gomes E, Rockwell P. Reactive oxygen species induced by proteasome inhibition in neuronal cells mediate mitochondrial dysfunction and a caspase-independent cell death. Apoptosis 2007; 12: 1389–1405.
32. Papa L, Rockwell P. Persistent mitochondrial dysfunction and oxidative stress hinder neuronal cell recovery from reversible proteasome inhibition. Apoptosis 2008; 13: 588–599.
33. Mahalingaiah PK, Ponnusamy L, Singh KP. Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells. Breast Cancer Res Treat 2015.
34. Haigis MC, Deng CX, Finley LW, Kim HS, Gius D. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res 2012; 72: 2468–2472.
35. Ma J, Zhang Q, Chen S, Fang B, Yang Q, Chen C et al. Mitochondrial dysfunction promotes breast cancer cell migration and invasion through HIF1alpha accumulation via increased production of reactive oxygen species. PloS One 2013; 8: e69485.
36. Barbosa JA, Silva LP, Teles RC, Esteves GF, Azevedo RB, Ventura MM et al. Crystal structure of the Bowman-Birk Inhibitor from Vigna unguiculata seeds in complex with beta-trypsin at 1.55 A resolution and its structural properties in association with proteinases. Biophys J 2007; 92: 1638–1650.
37. de Freitas SM, de Mello LV, da Silva MC, Vriend G, Neshich G, Ventura MM. Analysis of the black-eyed pea trypsin and chymotrypsin inhibitor-alpha-chymotrypsin complex. FEBS Lett 1997; 409: 121–127.
38. Silva LP, Liete JR SA, Bloch Jr C, Freitas SM. Thermal stability of a black eyed pea trypsin/chymotrypsin inhibitor (BTCI). Protein Pept Lett 2001; 7: 397–401.
39. Ventura MM X-FJ. Trypsin and chymotrypsin inhibitor from black-eyed pea (V. Sinensis L.) I. Purification and partial characterization. An Acad Bras Cienc 1966; 38: 553–566.
40. Souza Lda C, Camargo R, Demasi M, Santana JM, de Sa CM, de Freitas SM. Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells. PloS One 2014; 9: e86600.
41. Ventura MM, Xavier Filho J, Moreira RA, Aquino Ade M, Pinheiro PA. A trypsin and chymotrypsin inhibitor from black-eyed pea (Vigna sinensis L.). II. Further studies on its characterization and a reevaluation of earlier results. An Acad Bras Cienc 1971; 43: 233–242.
42. Kennedy AR. The evidence for soybean products as cancer preventive agents. J Nutr 1995; 125(3 Suppl): 733S–743S.
43. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 1998; 68(6 Suppl): 1406S–1412S.
44. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197–1200.
45. Barnes S, Grubbs C, Setchell KD, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 1990; 347: 239–253.
46. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386: 463–471.
47. Kunjappu MJ, Hochstrasser M. Assembly of the 20S proteasome. Biochim Biophys Acta 2014; 1843: 2–12.
48. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995; 268: 533–539.
49. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N et al. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 2002; 10: 609–618.
50. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015–1068.
51. Gavilan E, Giraldez S, Sanchez-Aguayo I, Romero F, Ruano D, Daza P. Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3beta dependent mechanism. Sci Rep 2015; 5: 10027.
52. Faust D, Schmitt C, Oesch F, Oesch-Bartlomowicz B, Schreck I, Weiss C et al. Differential p38-dependent signalling in response to cellular stress and mitogenic stimulation in fibroblasts. Cell Commun Signal 2012; 10: 6.
53. Pundir S, Vu HY, Solomon VR, McClure R, Lee H. VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centro-some amplification. Cancer Res 2015.
54. Keller JN, Hanni KB, Markesbery WR. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 2000; 113: 61–70.
55. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278: 33714–33723.
56. Ding Q, Keller JN. Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins. J Neurochem 2001; 77: 1010–1017.
57. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011; 21: 103–115.
58. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535–3540.
59. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076.
60. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638–2645.
61. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10: 361–369.
62. Dolcet X, Llobet D, Encinas M, Pallares J, Cabero A, Schoenenberger JA et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. JBiolChem2006; 281: 22118–22130.
63. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009; 114: 1046–1052.
64. Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S et al. Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKalpha. J Immunol 2013; 191: 2837–2846.
65. Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V et al. Proteasome inhibition increases recruitment of IkappaB kinase beta (IKKbeta), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 2014; 289: 2687–2700.
66. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007; 67: 2247–2255.
67. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102: 303–310.
68. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379.
69. Taylor RC, Adrain C, Martin SJ. Proteases, proteasomes and apoptosis: breaking Ub is hard to do. Cell Death Differ 2005; 12: 1213–1217.
70. Heinemeyer W, Trondle N, Albrecht G, Wolf DH. PRE5 and PRE6, the last missing genes encoding 20S proteasome subunits from yeast? Indication for a set of 14 different subunits in the eukaryotic proteasome core. Biochemistry 1994; 33: 12229–12237.
71. Schmidtke G, Kraft R, Kostka S, Henklein P, Frommel C, Lowe J et al. Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J 1996; 15: 6887–6898.
72. Demasi M, Shringarpure R, Davies KJ. Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Arch Biochem Biophys 2001; 389: 254–263.
73. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
74. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101–1108.